Reprogramming T Cells to Fight Glioblastoma
Time: 5:00 pm
day: Day Two
Details:
- Exploiting the preferential accumulation of Tregs in the tumor by therapeutically
altering their function - Discussing how the phenotype of GBM Tregs allows their selective targeting and
reduces immune-related adverse events - Pre-clinical data supporting αGITR with PD1 in GBM
